

9 March 2023

Incidence and treatment of breast cancer

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Please note: Aromatase Inhibitors are prescribed by GPs and therefore information is not available to the Trust. Figures will be for Main regimen.

- Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) : **6**
- Abemaciclib + Fulvestrant : **5**
- Alpelisib + Fulvestrant : **<5**
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent : **<5**
- Atezolizumab + Nab-paclitaxel/Paclitaxel : **<5**
- Capecitabine as a single agent : **17**
- Eribulin as a single agent or in combination : **<5**
- Everolimus + Exemestane : **<5**
- Fulvestrant as a single agent : **12**
- Lapatinib : **<5**
- Neratinib : **<5**
- Parp Inhibitors (Olaparib/Talazoparib) : **<5**
- Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) : **43**
- Palbociclib + Fulvestrant : **5**
- Pembrolizumab : **<5**
- Platinum (e.g. carboplatin or cisplatin) as a single agent : **<5**
- Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) : **13**
- Ribociclib + Fulvestrant : **<5**
- Sacituzumab Govitecan : **<5**
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent : **<5**
- Taxane and/or Anthracycline in combination : **83**
- Trastuzumab as a single agent or in combination : **63**
- Trastuzumab emtansine : **8**
- Transtuzumab deruxtecan : **<5**
- Any other active systemic anti-cancer therapy: **Goserelin 5, Vinorelbine 7 & Zoledronic Acid 16**

9 March 2023

Q2. Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with:

Of the 11 patients above:

- early/locally advanced breast cancer (Stages 1 to 3B) : **<10**
- advanced/metastatic breast cancer (Stages 3C and 4) : **<10**

Please note:

- Information as available from RISOH (regional information system Oncology & Haematology) Nov Jan 23
- Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.